NO314979B1 - Anvendelse av vismut for fremstilling av et preparat for behandling eller forebygging av en urogenital lidelse - Google Patents

Anvendelse av vismut for fremstilling av et preparat for behandling eller forebygging av en urogenital lidelse Download PDF

Info

Publication number: NO314979B1
Authority: NO; Norway
Prior art keywords: bismuth; preparation; administered; treatment; per day
Prior art date: 1995-12-07

Application number

NO19965191A

Other languages

English (en)

Norwegian (no)

Other versions

NO965191D0 (no

NO965191L (no

Inventor

Jamesina Anne Fitzgerald

Original Assignee

Procter & Gamble

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-07

Filing date

1996-12-05

Publication date

2003-06-23

1996-12-05 Application filed by Procter & Gamble filed Critical Procter & Gamble

1996-12-05 Publication of NO965191D0 publication Critical patent/NO965191D0/no

1997-06-09 Publication of NO965191L publication Critical patent/NO965191L/no

2003-06-23 Publication of NO314979B1 publication Critical patent/NO314979B1/no

Links

229910052797 bismuth Inorganic materials 0.000 title claims abstract description 52
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 title claims abstract description 52
208000025609 Urogenital disease Diseases 0.000 title claims abstract description 20
238000011282 treatment Methods 0.000 title claims abstract description 19
230000002265 prevention Effects 0.000 title claims abstract description 14
238000002360 preparation method Methods 0.000 title claims description 24
230000003071 parasitic effect Effects 0.000 claims abstract description 21
230000001404 mediated effect Effects 0.000 claims abstract description 13
241000224527 Trichomonas vaginalis Species 0.000 claims description 7
ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims description 6
229960000782 bismuth subsalicylate Drugs 0.000 claims description 6
KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 claims description 4
JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 claims description 4
229960000199 bismuth subgallate Drugs 0.000 claims description 4
SULICOHAQXOMED-YDXPQRMKSA-H dibismuth;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Bi+3].[Bi+3].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O SULICOHAQXOMED-YDXPQRMKSA-H 0.000 claims description 4
229940104825 bismuth aluminate Drugs 0.000 claims description 3
229960004645 bismuth subcitrate Drugs 0.000 claims description 3
PDSAKIXGSONUIX-UHFFFAOYSA-N hexaaluminum;dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3] PDSAKIXGSONUIX-UHFFFAOYSA-N 0.000 claims description 3
229910000014 Bismuth subcarbonate Inorganic materials 0.000 claims description 2
241001126846 Encephalitozoon hellem Species 0.000 claims description 2
MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 claims description 2
229940036358 bismuth subcarbonate Drugs 0.000 claims description 2
229940120293 vaginal suppository Drugs 0.000 claims description 2
239000006216 vaginal suppository Substances 0.000 claims description 2
238000000034 method Methods 0.000 abstract description 10
241001465754 Metazoa Species 0.000 abstract description 3
239000004599 antimicrobial Substances 0.000 description 22
208000015181 infectious disease Diseases 0.000 description 9
150000001621 bismuth Chemical class 0.000 description 6
208000030852 Parasitic disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 3
229960003159 atovaquone Drugs 0.000 description 3
KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 3
229960001482 bismuth subnitrate Drugs 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
206010013990 dysuria Diseases 0.000 description 3
239000002496 intravaginal dosage form Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940059082 douche Drugs 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
208000000143 urethritis Diseases 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
241000195940 Bryophyta Species 0.000 description 1
241000243234 Encephalitozoon Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
241000243190 Microsporidia Species 0.000 description 1
241001126829 Nosema Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241001492488 Pleistophora Species 0.000 description 1
208000010362 Protozoan Infections Diseases 0.000 description 1
HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010065584 Urethral stenosis Diseases 0.000 description 1
206010046914 Vaginal infection Diseases 0.000 description 1
201000008100 Vaginitis Diseases 0.000 description 1
206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
-1 araoxicillin Chemical compound 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
150000001622 bismuth compounds Chemical class 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229960002328 chloroquine phosphate Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229960000691 diiodohydroxyquinoline Drugs 0.000 description 1
208000028659 discharge Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
UXZFQZANDVDGMM-UHFFFAOYSA-N iodoquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229960000901 mepacrine Drugs 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
235000011929 mousse Nutrition 0.000 description 1
229960000564 nitrofurantoin Drugs 0.000 description 1
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940101070 pepto-bismol Drugs 0.000 description 1
210000002640 perineum Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
229960000611 pyrimethamine Drugs 0.000 description 1
GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
239000012487 rinsing solution Substances 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960005053 tinidazole Drugs 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
SPRBJFWIUVWXBT-UHFFFAOYSA-K tripotassium 2-hydroxypropane-1,2,3-tricarboxylate 2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [K+].[K+].[K+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SPRBJFWIUVWXBT-UHFFFAOYSA-K 0.000 description 1
201000001988 urethral stricture Diseases 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
208000013464 vaginal disease Diseases 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19965191A 1995-12-07 1996-12-05 Anvendelse av vismut for fremstilling av et preparat for behandling eller forebygging av en urogenital lidelse NO314979B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US56885295A	1995-12-07	1995-12-07

Publications (3)

Publication Number	Publication Date
NO965191D0 NO965191D0 (no)	1996-12-05
NO965191L NO965191L (no)	1997-06-09
NO314979B1 true NO314979B1 (no)	2003-06-23

Family

ID=24273004

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19965191A NO314979B1 (no)	1995-12-07	1996-12-05	Anvendelse av vismut for fremstilling av et preparat for behandling eller forebygging av en urogenital lidelse

Country Status (8)

Country	Link
US (1)	US5882686A (de)
EP (1)	EP0776665B1 (de)
AT (1)	ATE232736T1 (de)
DE (1)	DE69626260T2 (de)
DK (1)	DK0776665T3 (de)
ES (1)	ES2192219T3 (de)
NO (1)	NO314979B1 (de)
PT (1)	PT776665E (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2767699A1 (fr)	1997-08-28	1999-02-26	Oreal	Composition filmogene epaissie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR962163A (de) *		1950-06-02
US4049817A (en) *	1972-08-14	1977-09-20	Sandoz Ltd.	Synergistic compositions
US4514421A (en) *	1979-08-30	1985-04-30	Herschler R J	Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it
US5256684A (en) *	1985-06-13	1993-10-26	The Procter & Gamble Company	Methods and compositions for the treatment of gastrointestinal disorders
JPS63174926A (ja) *	1987-01-09	1988-07-19	Nitto Kasei Kk	家禽用抗コクシジウム剤
US5221664A (en) *	1990-04-23	1993-06-22	Magainin Pharmaaceuticals Inc.	Composition and treatment with biologically active peptides and toxic cations
DE69117955T2 (de) *	1990-07-20	1996-09-19	Tillotts Pharma Ag, Ziefen	Produkte und verfahren zur behandlung des verdauungskanals
AUPM596894A0 (en) *	1994-05-30	1994-06-23	Hybrid Scientific Pty Ltd	Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders

1996
- 1996-12-05 DE DE69626260T patent/DE69626260T2/de not_active Expired - Fee Related
- 1996-12-05 NO NO19965191A patent/NO314979B1/no unknown
- 1996-12-05 DK DK96308853T patent/DK0776665T3/da active
- 1996-12-05 AT AT96308853T patent/ATE232736T1/de not_active IP Right Cessation
- 1996-12-05 PT PT96308853T patent/PT776665E/pt unknown
- 1996-12-05 EP EP96308853A patent/EP0776665B1/de not_active Expired - Lifetime
- 1996-12-05 ES ES96308853T patent/ES2192219T3/es not_active Expired - Lifetime
1997
- 1997-09-04 US US08/923,831 patent/US5882686A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT776665E (pt)	2003-06-30
DE69626260D1 (de)	2003-03-27
NO965191D0 (no)	1996-12-05
DK0776665T3 (da)	2003-03-31
US5882686A (en)	1999-03-16
ES2192219T3 (es)	2003-10-01
NO965191L (no)	1997-06-09
DE69626260T2 (de)	2003-12-04
EP0776665A1 (de)	1997-06-04
ATE232736T1 (de)	2003-03-15
EP0776665B1 (de)	2003-02-19

Publication	Publication Date	Title
Ávila et al.	2021	Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: a randomized clinical trial
Soper et al.	1993	Prevention of vaginal trichomoniasis by compliant use of the female condom
Ishibashi et al.	1990	Oral itraconazole and topical miconazole with debridement for Acanthamoeba keratitis
Lister et al.	1993	Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men
Caselli et al.	1997	Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication ofHelicobacter pylori
EP0772445B1 (de)	2004-03-31	Pharmazeutische präparate, insbesondere ovula, die viele verschiedene aktive bestandteile enthalten
Swindell et al.	1983	Audits of antibiotic prescribing in a Bristol hospital.
Ballagh et al.	2002	Safety of single daily use for one week of C31G HEC gel in women
JP2669818B2 (ja)	1997-10-29	胃腸障害の治療及び予防のためのニトロフラントインの使用
NO314979B1 (no)	2003-06-23	Anvendelse av vismut for fremstilling av et preparat for behandling eller forebygging av en urogenital lidelse
US5827543A (en)	1998-10-27	Methods and compositions for the prevention and treatment of urogenital disorders
Theodore	1950	Use of sodium propionate in external infections of the eyes
Worm et al.	1995	Azithromycin levels in cervical mucus and plasma after a single 1.0 g oral dose for chlamydial cervicitis.
Antonelli et al.	2000	A randomized trial of intravaginal nonoxynol 9 versus oral metronidazole in the treatment of vaginal trichomoniasis
Ladipo et al.	2000	A new vaginal antimicrobial contraceptive formulation: phase I clinical pilot studies
Sholten et al.	1977	Parasitism in an Ontario mental institution: preliminary report
Mondanaro	1981	Reproductive health concerns for the treatment of drug dependent women
Omar et al.	2022	A Pre–Phase III Efficacy Trial of the Spermicide/Contraceptive Effect of the Invisible Condom, a Non-Hormonal Vaginal Gel, in Women from Canada
JP2023528884A (ja)	2023-07-06	疾患の処置用の２－（ジエチルアミノ）エチル２－（４－イソブチルフェニル）プロピオネートの局所投与
Pentland et al.	1981	Failure of ejaculation with indoramin
Gonen et al.	1985	Short-term prophylactic antibiotic for elective abdominal hysterectomy: how short?
PERL et al.	1963	Further studies in treatment of female and male trichomoniasis with metronidazole
AL-Khikani	2020	Refractory Fungal Vaginitis Treated By Topical Amphotericin B. Review
RU2195945C2 (ru)	2003-01-10	Способ лечения инфекций, передаваемых половым путем
KOLMER	1930	Bismuth arsphenamine sulphonate (bismarsen) in the treatment of syphilis and of other spirochetic infections